Metabolomics in hypertension

Journal of Hypertension

Volumn 32, Issue 6, 2014, Pages 1159-1169

  Nikolic, Sonja B ^a   Sharman, James E ^a   Adams, Murray J ^b   Edwards, Lindsay M ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

biomarkers; blood pressure; mass spectrometry; metabolomics; NMR spectroscopy; pharmacometabolomics

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; APOLIPOPROTEIN B; FATTY ACID; HIGH DENSITY LIPOPROTEIN 3; LIPOPROTEIN A; BIOLOGICAL MARKER;

ADIPOCYTE; CARDIOVASCULAR RISK; CELL SEPARATION; CLINICAL TRIAL (TOPIC); ELECTROSPRAY; ESSENTIAL HYPERTENSION; GAS CHROMATOGRAPHY; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; MASKED HYPERTENSION; MASS SPECTROMETRY; MATERNAL HYPERTENSION; METABOLOME; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEINURIA; RADIOFREQUENCY; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WHITE COAT HYPERTENSION; ANIMAL; CARDIOVASCULAR DISEASE; METABOLISM; MORTALITY; REPRODUCIBILITY; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; METABOLOMICS; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84900395011     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000168     Document Type: Review

References (90)

1. Psaty BM, Furberg CD, Kuller LH, Cushman M, Savage PJ, Levine D, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001; 161:1183-1192.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
3. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
4. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000; 101:329-335.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
6. Pannier BM, Cambillau MS, Vellaud V, Atger V, Moatti N, Safar ME. Abnormalities of lipid metabolism and arterial rigidity in young subjects with borderline hypertension. Clin Invest Med 1994; 17:42-51.
7. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130:606-625.
8. Griffin JL the Cinderella story of metabolic profiling: does metabo-lomics get to go to the functional genomics ball? Phil Trans R Soc Lond B Biol Sci 2006; 361:147-161.
9. Nicholson JK, O'Flynn MP, Sadler PJ, Macleod AF, Juul SM, Sonksen PH. Proton-nuclear-magnetic-resonance studies of serum, plasma and urine from fasting normal and diabetic subjects. Biochem J 1984; 217:365-375.
10. Sauer U, Heinemann M, Zamboni N. Genetics. Getting closer to the whole picture. Science 2007; 316:550-551.
11. Jones GL, Sang E, Goddard C, Mortishire-Smith RJ, Sweatman BC, Haselden JN, et al. A functional analysis of mouse models of cardiac disease through metabolic profiling. J Biol Chem 2005; 280:7530-7539.
12. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457:910-914.
13. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008; 21:9-27.
14. Akira K, Masu S, Imachi M, Mitome H, Hashimoto M, Hashimoto T. 1H NMR-based metabonomic analysis of urine from young spontaneously hypertensive rats. J Pharm Biomed Anal 2008; 46:550-556.
15. Fujiwara M, Arifuku K, Ando I, Nemoto T. Pattern recognition analysis for classification of hypertensive model rats and diurnal variation using 1H-NMR spectroscopy of urine. Anal Sci 2005; 21:1259-1262.
16. Akira K, Imachi M, Hashimoto T. Investigations into biochemical changes of genetic hypertensive rats using 1H nuclear magnetic resonance-based metabonomics. Hypertens Res 2005; 28:425-430.
17. Aa JY, Wang GJ, Hao HP, Huang Q, Lu YH, Yan B, et al. Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats. Acta Pharmacol Sin 2010; 31:930-937.
18. Lu Y, Jiye A, Wang G, Hao H, Huang Q, Yan B, et al. Gas chroma-tography/time-of-flight mass spectrometry based metabonomic approach to differentiating hypertension-and age-related metabolic variation in spontaneously hypertensive rats. Rapid Commun Mass Spectrom 2008; 22:2882-2888.
19. Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E. Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003; 128:32-36.
20. Liu Y, Chen T, Qiu Y, Cheng Y, Cao Y, Zhao A, Jia W. An ultrasonication-assisted extraction and derivatization protocol for GC/TOFMS-based metabolite profiling. Anal Bioanal Chem 2011; 400:1405-1417.
21. De Meyer T, Sinnaeve D, Van Gasse B, Tsiporkova E, Rietzschel ER, De Buyzere ML, et al. NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Anal Chem 2008; 80:3783-3790.
22. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008; 453:396-400.
23. Zheng Y, Yu B, Alexander D, Manolio TA, Aguilar D, Coresh J, et al. Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study. Am J Epidemiol 2013; 178:534-542.
24. Nikolic SB, Wilson R, Hare JL, Marwick TH, Edwards LM, Sharman JE. Spironolactone reduces aortic stiffness via blood pressure-dependent effects of canrenoate. Metabolomics 2014; 10:105-113.
25. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, et al the human serum metabolome. PLoS One 2011; 6:e16957.
26. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0: the human metabolome database in 2013. Nucleic Acids Res 2013; 41:D801-807.
27. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the human metabolome database. Nucleic Acids Res 2007; 35:D521-526.
28. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res 2007; 6:443-458.
29. Atherton HJ, Gulston MK, Bailey NJ, Cheng KK, Zhang W, Clarke K, Griffin JL. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse. Mol Syst Biol 2009; 5:259.
30. Bothwell JH, Griffin JL. An introduction to biological nuclear magnetic resonance spectroscopy. Biol Rev Camb Philos Soc 2011; 86:493-510.
31. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spec-trometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev 2011; 40:387-426.
32. Nordstrom A, Want E, Northen T, Lehtio J, Siuzdak G. Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. Anal Chem 2008; 80:421-429.
33. Wishart DS. Advances in metabolite identification. Bioanalysis 2011; 3:1769-1782.
34. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatog-raphy coupled to mass spectrometry. Nat Protoc 2011; 6:1060-1083.
35. Paglia G, Hrafnsdottir S, Magnusdottir M, Fleming RM, Thorlacius S, Palsson BO, Thiele I. Monitoring metabolites consumption and secretion in cultured cells using ultra-performance liquid chromatog-raphy quadrupole-time of flight mass spectrometry (UPLC-Q-ToF-MS). Anal Bioanal Chem 2012; 402:1183-1198.
36. Theodoridis G, Gika HG, Wilson ID. Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass Spectrom Rev 2011; 30:884-906.
37. Kell DB, Brown M, Davey HM, Dunn WB, Spasic I, Oliver SG. Metabolic footprinting and systems biology: the medium is the message. Nat Rev Microbiol 2005; 3:557-565.
38. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-465.
39. Wu H, Southam AD, Hines A, Viant MR. High-throughput tissue extraction protocol for NMR-and MS-based metabolomics. Anal Biochem 2008; 372:204-212.
40. Musgrove RE, Horne J, Wilson R, Edwards LM, Dickson TC the metabolomics of alpha-synuclein (SNCA) gene deletion and mutation in mouse brain. Metabolomics 2014; 10:114-122.
41. Grouzmann E, Cavadas C, Grand D, Moratel M, Aubert JF, Brunner HR, Mazzolai L. Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice. Pflugers Arch 2003; 447:254-258.
42. Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am J Clin Nutr 2006; 84:531-539.
43. Barton RH, Waterman D, Bonner FW, Holmes E, Clarke R, Procardis C, et al the influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol Biosyst 2010; 6:215-224.
44. Drake SK, Bowen RA, Remaley AT, Hortin GL. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin Chem 2004; 50:2398-2401.
45. Deprez S, Sweatman BC, Connor SC, Haselden JN, Waterfield CJ. Optimisation of collection, storage and preparation of rat plasma for 1H NMR spectroscopic analysis in toxicology studies to determine inherent variation in biochemical profiles. J Pharm Biomed Anal 2002; 30:1297-1310.
46. Brinc D, Chan MK, Venner AA, Pasic MD, Colantonio D, Kyriakopolou L, Adeli K. Long-term stability of biochemical markers in pediatric serum specimens stored at-80 degrees C: a CALIPER Substudy. Clin Biochem 2012; 45:816-826.
47. Trabi M, Keller MD, Johnsson NN. NMR-based metabonomics of bovine blood: an investigation into the effects of long term storage on plasma samples. Metabolomics 2013; 9:1041-1047.
48. Teahan O, Gamble S, Holmes E, Waxman J, Nicholson JK, Bevan C, Keun HC. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem 2006; 78:4307-4318.
49. Moka D, Vorreuther R, Schicha H, Spraul M, Humpfer E, Lipinski M, et al. Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spec-troscopy. J Pharm Biomed Anal 1998; 17:125-132.
50. Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the postgenomic era. Bioessays 2004; 26:99-105.
51. Broadhurst DI, Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006; 2:171-196.
52. Ebbels TM, Holmes E, Lindon JC, Nicholson JK. Evaluation of metabolic variation in normal rat strains from a statistical analysis of 1H NMR spectra of urine. J Pharm Biomed Anal 2004; 36:823-833.
53. Solanky KS, Bailey NJ, Beckwith-Hall BM, Davis A, Bingham S, Holmes E, et al. Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. Anal Biochem 2003; 323:197-204.
54. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace AA, Schofield PM, et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006; 12:705-710.
55. Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem 2004; 50:1189-1200.
56. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol 2002; 90:77i-84i.
57. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
58. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8:1439-1444.
59. Qi S, Ouyang X, Wang L, Peng W, Wen J, Dai Y. A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1) H-NMR-spectroscopy. Clin Transl Sci 2012; 5:379-385.
60. Pinto YM, Paul M, Ganten D.Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998; 39:77-88.
61. Vargas SL, Toma I, Kang JJ, Meer EJ, Peti-Peterdi J. Activation of the succinate receptor GPR91 in macula densa cells causes renin release. J Am Soc Nephrol 2009; 20:1002-1011.
62. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004; 429:188-193.
63. Militante JD, Lombardini JB. Treatment of hypertension with oral taurine: experimental and clinical studies. Amino Acids 2002; 23:381-393.
64. Fujita T, Ando K, Noda H, Ito Y, Sato Y. Effects of increased adreno-medullary activity and taurine in young patients with borderline hypertension. Circulation 1987; 75:525-532.
65. Nara Y, Yamori Y, Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharmacol 1978; 27:2689-2692.
66. Muratani H, Ferrario CM, Averill DB. Ventrolateral medulla in spontaneously hypertensive rats: role of angiotensin II. Am J Physiol 1993; 264:R388-R395.
67. Akira K, Mitome H, Imachi M, Shida Y, Miyaoka H, Hashimoto T. LC-NMR identification of a novel taurine-related metabolite observed in (1)H NMR-based metabonomics of genetically hypertensive rats. J Pharm Biomed Anal 2010; 51:1091-1096.
68. Wilkinson I, Cockcroft JR. Cholesterol, lipids and arterial stiffness. Adv Cardiol 2007; 44:261-277.
69. Egan BM SK. Evidence linking fatty fat acids, the risk factor cluster, and vascular pathophysiology. Implications for the diabetic hypertensive patient. In Endocrinology of the vasculature, contemporary endocrinology, Vol. 1. Humana Press; 1996. pp. 157-172.
70. Ordway RW, Singer JJ, Walsh JV Jr. Direct regulation of ion channels by fatty acids. Trends Neurosci 1991; 14:96-100.
71. Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Duci-metiere P, Eschwege E. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol 1998; 27:808-813.
72. Tugrul A, Guldiken S, Ugur-Altun B, Arikan E. An evaluation of glucose tolerance in essential hypertension. Yonsei Med J 2009; 50:195-199.
73. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12:1623-1635.
74. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al., Screening for Pregnancy Endpoints C. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010; 56:741-749.
75. Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, Dietzen DJ. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat Diagn 2011; 31:990-994.
76. Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. Metabolomics and first-trimester prediction of early-onset preeclamp-sia. J Matern Fetal Neonatal Med 2012; 25:1840-1847.
77. Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, et al. First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol 2013; 208:58e51-58e57.
78. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183:S1-S22.
79. Martin CA, McGrath BP. White-coat hypertension. Clin Exp Pharmacol Physiol 2014; 41:22-29.
80. Franklin SS, Thijs L, Li Y, Hansen TW, Boggia J, Liu Y, et al. Masked hypertension in diabetes mellitus: treatment implications for clinical practice. Hypertension 2013; 61: 964-971.
81. Head GA, McGrath BP, Mihailidou AS, Nelson MR, Schlaich MP, Stowasser M, et al. Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. J Hypertens 2012; 30:253-266.
82. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. J Am Med Assoc 2004; 291:1342-1349.
83. Vaughan M, Berger JE, Steinberg D. Hormone-sensitive lipase and monoglyceride lipase activities in adipose tissue. J Biol Chem 1964; 239:401-409.
84. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M, Heiss G. Arterial stiffness and the development of hypertension the ARIC study. Hypertension 1999; 34:201-206.
85. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
86. Mamas M, Dunn WB, Neyses L, Goodacre R the role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011; 85:5-17.
87. Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004; 5:709-719.
88. Nicholson JK, Everett JR, Lindon JC. Longitudinal pharmacometabo-nomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin Drug Metab Toxicol 2012; 8:135-139.
89. Corona G, Rizzolio F, Giordano A, Toffoli G. Pharmaco-metabolomics: an emerging 'omics' tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol 2012; 227:2827-2831.
90. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440:1073-1077.